Information

Dear user, the application need JavaScript support. Please enable JavaScript in your browser.

English (EN)·Polski (PL)·Ukraiński (UK)
Go to the home page of the library Uniwersytet Ekonomiczny we Wrocławiu Link opens in a new window Library logo Prolib Integro - home pageUniwersytet Ekonomiczny we Wrocławiu

You search for a phrase ""Lymphoma, Non-Hodgkin"" according to the criterion: Subject Terms

  Filters
Align
Showing 1-20 from 3124 results
Title:
B-Cell Activation Biomarkers in Salivary Glands Are Related to Lymphomagenesis in Primary Sjögren's Disease: A Pilot Monocentric Exploratory Study.
Authors:
Bruno D; Clinical Immunology Unit, Fondazione Policlinico Universitario A. Gemelli-IRCCS, 00168 Rome, Italy.; Department of Medicine, University of Verona, 37129 Verona, Italy.
Tolusso B; Immunology Core Facility, Gemelli Science and Technology Park, Fondazione Policlinico Universitario A. Gemelli-IRCCS, 00168 Rome, Italy.
Lugli G; Rare Disease Unit, Meyer Children's Hospital IRCCS, 50139 Florence, Italy.
Di Mario C; Immunology Core Facility, Gemelli Science and Technology Park, Fondazione Policlinico Universitario A. Gemelli-IRCCS, 00168 Rome, Italy.
Petricca L; Rheumatology Division, Fondazione Policlinico Universitario A. Gemelli-IRCCS, 00168 Rome, Italy.
Perniola S; Clinical Immunology Unit, Fondazione Policlinico Universitario A. Gemelli-IRCCS, 00168 Rome, Italy.
Bui L; Institute of Pathology, Fondazione Policlinico Universitario A. Gemelli-IRCCS, 00168 Rome, Italy.
Benvenuto R; Institute of Pathology, Fondazione Policlinico Universitario A. Gemelli-IRCCS, 00168 Rome, Italy.
Ferraccioli G; Department of Internal Medicine, Catholic University of the Sacred Heart, 00168 Rome, Italy.
Alivernini S; Immunology Core Facility, Gemelli Science and Technology Park, Fondazione Policlinico Universitario A. Gemelli-IRCCS, 00168 Rome, Italy.; Rheumatology Division, Fondazione Policlinico Universitario A. Gemelli-IRCCS, 00168 Rome, Italy.; Department of Internal Medicine, Catholic University of the Sacred Heart, 00168 Rome, Italy.
Gremese E; Clinical Immunology Unit, Fondazione Policlinico Universitario A. Gemelli-IRCCS, 00168 Rome, Italy.; Immunology Core Facility, Gemelli Science and Technology Park, Fondazione Policlinico Universitario A. Gemelli-IRCCS, 00168 Rome, Italy.; Department of Internal Medicine, Catholic University of the Sacred Heart, 00168 Rome, Italy.
Show more
Source:
International journal of molecular sciences [Int J Mol Sci] 2024 Mar 13; Vol. 25 (6). Date of Electronic Publication: 2024 Mar 13.
Publication Type:
Journal Article
MeSH Terms:
Sjogren's Syndrome*/diagnosis
Lymphoma, Non-Hodgkin*/genetics
Lymphoma, Non-Hodgkin*/complications
MicroRNAs*/genetics
MicroRNAs*/metabolism
Humans ; Salivary Glands/metabolism ; Salivary Glands, Minor/pathology ; Biomarkers/metabolism
Academic Journal
Full Text  Link opens in a new window Full TextDetails
Title:
Incidence and survival of second primary non-Hodgkin lymphoma: A Surveillance, Epidemiology, and End Results-based cohort study.
Authors:
Yu N; Departments of Lymphatic and Hematological Oncology, Jiangxi Cancer Hospital (The Second Affiliated Hospital of Nanchang Medical College), Nanchang, Jiangxi, P.R. China.
Zhang W; Departments of Lymphatic and Hematological Oncology, Jiangxi Cancer Hospital (The Second Affiliated Hospital of Nanchang Medical College), Nanchang, Jiangxi, P.R. China.
Zhong X; Departments of Lymphatic and Hematological Oncology, Jiangxi Cancer Hospital (The Second Affiliated Hospital of Nanchang Medical College), Nanchang, Jiangxi, P.R. China.
Song X; Departments of Lymphatic and Hematological Oncology, Jiangxi Cancer Hospital (The Second Affiliated Hospital of Nanchang Medical College), Nanchang, Jiangxi, P.R. China.
Li W; Departments of Lymphatic and Hematological Oncology, Jiangxi Cancer Hospital (The Second Affiliated Hospital of Nanchang Medical College), Nanchang, Jiangxi, P.R. China.
Show more
Source:
PloS one [PLoS One] 2024 Mar 11; Vol. 19 (3), pp. e0300330. Date of Electronic Publication: 2024 Mar 11 (Print Publication: 2024).
Publication Type:
Journal Article
MeSH Terms:
Lymphoma, Non-Hodgkin*/therapy
Lymphoma, Non-Hodgkin*/drug therapy
Humans ; Male ; Adult ; Middle Aged ; Female ; Cohort Studies ; Retrospective Studies ; Incidence ; SEER Program ; Prognosis
Academic Journal
Full Text  Link opens in a new window Full TextDetails
Title:
Global burden, risk factors, and trends of non-Hodgkin lymphoma: A worldwide analysis of cancer registries.
Authors:
Huang J; The Jockey Club School of Public Health and Primary Care, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong SAR, China.; Centre for Health Education and Health Promotion, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.
Chan SC; The Jockey Club School of Public Health and Primary Care, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong SAR, China.
Lok V; Department of Global Public Health, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.
Zhang L; Suzhou Industrial Park Monash Research Institute of Science and Technology, Suzhou, China.; The School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Lucero-Prisno DE 3rd; Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London, UK.
Xu W; School of Public Health, Fudan University, Shanghai, China.
Zheng ZJ; Department of Global Health, School of Public Health, Peking University, Beijing, China.
Elcarte E; University of the Philippines, Manila, Philippines.
Withers M; Department of Population and Health Sciences, Institute for Global Health, University of Southern California, Los Angeles, California, USA.
Wong MCS; The Jockey Club School of Public Health and Primary Care, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong SAR, China.; Centre for Health Education and Health Promotion, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.; Department of Global Health, School of Public Health, Peking University, Beijing, China.
Show more
Source:
Cancer medicine [Cancer Med] 2024 Mar; Vol. 13 (5), pp. e7056.
Publication Type:
Journal Article
MeSH Terms:
Lymphoma, Non-Hodgkin*/epidemiology
Lymphoma*/epidemiology
Humans ; Male ; Female ; Incidence ; Registries ; Risk Factors ; Global Health
Academic Journal
Full Text  Link opens in a new window Full TextDetails
Title:
Evaluation of the potential impact on pharmacokinetics of various cytochrome P450 substrates of increasing IL-6 levels following administration of the T-cell bispecific engager glofitamab.
Authors:
Djebli N; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, Basel, Switzerland.; Luzsana Biotechnology, Clinical Pharmacology and Early Development, Basel, Switzerland.
Parrott N; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, Basel, Switzerland.
Jaminion F; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, Basel, Switzerland.
O'Jeanson A; Department of Pharmacy, Uppsala University, Uppsala, Sweden.
Guerini E; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, Basel, Switzerland.
Carlile D; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, Welwyn, UK.
Show more
Source:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2024 Mar; Vol. 13 (3), pp. 396-409. Date of Electronic Publication: 2023 Dec 14.
Publication Type:
Journal Article
MeSH Terms:
Cytochrome P-450 CYP1A2*
Lymphoma, Non-Hodgkin*/drug therapy
Antibodies, Bispecific*
Humans ; Interleukin-6 ; Cytochrome P-450 CYP3A/metabolism ; Cytochrome P-450 CYP2C9/metabolism ; Drug Interactions ; T-Lymphocytes/metabolism ; Cytochrome P-450 Enzyme System/metabolism ; Models, Biological
Academic Journal
Full Text  Link opens in a new window Full TextDetails
Title:
Long-term monitoring of gastric mucosa-associated lymphoid tissue lymphoma in patients with extra copies of the MALT1 gene.
Authors:
Iwamuro M; Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan. .
Takenaka R; Department of Internal Medicine, Tsuyama Chuo Hospital, Tsuyama, 708‑0841, Japan.
Miyahara K; Department of Internal Medicine, Hiroshima City Hospital, Hiroshima, 730-8518, Japan.
Okanoue S; Department of Gastroenterology, Mitoyo General Hospital, Kanonji, 769‑1695, Japan.
Yoshioka M; Department of Internal Medicine, Okayama Saiseikai General Hospital, Okayama, 700‑8511, Japan.
Sakaguchi C; Department of Gastroenterology, Shikoku Cancer Center, Matsuyama, 791-0280, Japan.
Yamamoto K; Department of Gastroenterology, Kagawa Prefectural Central Hospital, Takamatsu, 760‑8557, Japan.
Kawai Y; Department of Gastroenterology, Onomichi Municipal Hospital, Onomichi, 722‑8503, Japan.
Toyokawa T; Department of Gastroenterology, Fukuyama Medical Center, Fukuyama, 720‑8520, Japan.
Tanaka T; Department of Pathology, Okayama University Hospital, Okayama, 700-8558, Japan.
Otsuka M; Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.
Show more
Source:
Scientific reports [Sci Rep] 2024 Feb 29; Vol. 14 (1), pp. 4953. Date of Electronic Publication: 2024 Feb 29.
Publication Type:
Multicenter Study; Journal Article
MeSH Terms:
Lymphoma, B-Cell, Marginal Zone*/genetics
Lymphoma, B-Cell, Marginal Zone*/pathology
Lymphoma, Non-Hodgkin*
Stomach Neoplasms*
Humans ; In Situ Hybridization, Fluorescence ; Retrospective Studies ; Neoplasm Recurrence, Local/genetics ; Translocation, Genetic ; Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein/genetics
SCR Disease Name:
Familial primary gastric lymphoma
Academic Journal
Full Text  Link opens in a new window Full TextDetails
Title:
Primary thyroid lymphoma: a case series.
Authors:
Sakhri S; Department of Surgical Oncology, Salah Azaiez Institute, Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia.
Zemni I; Department of Surgical Oncology, Salah Azaiez Institute, Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia. .; LMBA (LR03ES03), Sciences Faculty of Tunis, University Tunis El Manar, Tunis, Tunisia. .
Ayadi MA; Department of Surgical Oncology, Salah Azaiez Institute, Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia.; LMBA (LR03ES03), Sciences Faculty of Tunis, University Tunis El Manar, Tunis, Tunisia.
Kamoun S; Department of Pathology, Salah Azaïz Institute, Faculty of Medicine, University Tunis El Manar, Tunis, Tunisia.
Chargui R; Department of Surgical Oncology, Salah Azaiez Institute, Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia.
Ben Dhiab T; Department of Surgical Oncology, Salah Azaiez Institute, Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia.
Show more
Source:
Journal of medical case reports [J Med Case Rep] 2024 Feb 24; Vol. 18 (1), pp. 108. Date of Electronic Publication: 2024 Feb 24.
Publication Type:
Case Reports; Journal Article
MeSH Terms:
Thyroid Neoplasms*/pathology
Lymphoma, Non-Hodgkin*
Lymphoma, Large B-Cell, Diffuse*/diagnosis
Lymphoma, Large B-Cell, Diffuse*/therapy
Lymphoma, Large B-Cell, Diffuse*/pathology
Male ; Humans ; Female ; Aged ; Rare Diseases ; Doxorubicin/therapeutic use ; Prednisone/therapeutic use ; Vincristine/therapeutic use ; Rituximab ; Cyclophosphamide/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Academic Journal
Full Text  Link opens in a new window Full TextDetails
Title:
Initial Efficacy of the COVID-19 mRNA Vaccine Booster and Subsequent Breakthrough Omicron Variant Infection in Patients with B-Cell Non-Hodgkin's Lymphoma: A Single-Center Cohort Study.
Authors:
Saito M; Blood Disorders Center, Aiiku Hospital, Sapporo 064-0804, Hokkaido, Japan.
Mori A; Blood Disorders Center, Aiiku Hospital, Sapporo 064-0804, Hokkaido, Japan.
Ishio T; Blood Disorders Center, Aiiku Hospital, Sapporo 064-0804, Hokkaido, Japan.
Kobayashi M; Blood Disorders Center, Aiiku Hospital, Sapporo 064-0804, Hokkaido, Japan.
Tsukamoto S; Blood Disorders Center, Aiiku Hospital, Sapporo 064-0804, Hokkaido, Japan.
Kajikawa S; Blood Disorders Center, Aiiku Hospital, Sapporo 064-0804, Hokkaido, Japan.
Yokoyama E; Blood Disorders Center, Aiiku Hospital, Sapporo 064-0804, Hokkaido, Japan.
Kanaya M; Blood Disorders Center, Aiiku Hospital, Sapporo 064-0804, Hokkaido, Japan.
Izumiyama K; Blood Disorders Center, Aiiku Hospital, Sapporo 064-0804, Hokkaido, Japan.
Muraki H; Division of Laboratory, Aiiku Hospital, Sapporo 064-0804, Hokkaido, Japan.
Morioka M; Blood Disorders Center, Aiiku Hospital, Sapporo 064-0804, Hokkaido, Japan.
Kondo T; Blood Disorders Center, Aiiku Hospital, Sapporo 064-0804, Hokkaido, Japan.
Show more
Source:
Viruses [Viruses] 2024 Feb 21; Vol. 16 (3). Date of Electronic Publication: 2024 Feb 21.
Publication Type:
Journal Article
MeSH Terms:
COVID-19*/prevention & control
Lymphoma*
Lymphoma, Non-Hodgkin*/drug therapy
Humans ; COVID-19 Vaccines ; mRNA Vaccines ; Breakthrough Infections ; Cohort Studies ; SARS-CoV-2/genetics ; RNA, Messenger ; Vaccination ; Antibodies, Viral
SCR Organism:
SARS-CoV-2 variants
Academic Journal
Full Text  Link opens in a new window Full TextDetails
Title:
Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study.
Authors:
Zhang Y; Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, 3400 Civic Center Boulevard, Perelman Center for Advanced Medicine, SPE 8-112, Philadelphia, PA, 19104, USA.; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Patel RP; Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, 3400 Civic Center Boulevard, Perelman Center for Advanced Medicine, SPE 8-112, Philadelphia, PA, 19104, USA.; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Kim KH; Biopharmaceutical Research Center, AbClon Inc., #1401, Ace Twin Tower1, 285 Digital-Ro, Guro-Gu, Seoul, Korea.
Cho H; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-Ro 43-Gil, Songpa-Gu, Seoul, Korea.
Jo JC; Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
Jeong SH; Ajou University Hospital, Suwon, Korea.
Oh SY; Division of Hematology-Oncology, Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea.
Choi YS; Ajou University Hospital, Suwon, Korea.
Kim SH; Division of Hematology-Oncology, Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea.
Lee JH; Division of Hematology-Oncology, Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea.
Angelos M; Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, 3400 Civic Center Boulevard, Perelman Center for Advanced Medicine, SPE 8-112, Philadelphia, PA, 19104, USA.; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Guruprasad P; Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, 3400 Civic Center Boulevard, Perelman Center for Advanced Medicine, SPE 8-112, Philadelphia, PA, 19104, USA.; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Cohen I; Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, 3400 Civic Center Boulevard, Perelman Center for Advanced Medicine, SPE 8-112, Philadelphia, PA, 19104, USA.; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Ugwuanyi O; Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, 3400 Civic Center Boulevard, Perelman Center for Advanced Medicine, SPE 8-112, Philadelphia, PA, 19104, USA.; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Lee YG; Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, 3400 Civic Center Boulevard, Perelman Center for Advanced Medicine, SPE 8-112, Philadelphia, PA, 19104, USA.; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; College of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan, Korea.
Pajarillo R; Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, 3400 Civic Center Boulevard, Perelman Center for Advanced Medicine, SPE 8-112, Philadelphia, PA, 19104, USA.; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Cho JH; Department of Pathology, Immunology and Laboratory Medicine, Rutgers New Jersey Medical School, Newark, NJ, USA.
Carturan A; Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, 3400 Civic Center Boulevard, Perelman Center for Advanced Medicine, SPE 8-112, Philadelphia, PA, 19104, USA.; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Paruzzo L; Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, 3400 Civic Center Boulevard, Perelman Center for Advanced Medicine, SPE 8-112, Philadelphia, PA, 19104, USA.; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Ghilardi G; Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, 3400 Civic Center Boulevard, Perelman Center for Advanced Medicine, SPE 8-112, Philadelphia, PA, 19104, USA.; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Wang M; Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, 3400 Civic Center Boulevard, Perelman Center for Advanced Medicine, SPE 8-112, Philadelphia, PA, 19104, USA.; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Kim S; Biopharmaceutical Research Center, AbClon Inc., #1401, Ace Twin Tower1, 285 Digital-Ro, Guro-Gu, Seoul, Korea.
Kim SM; Biopharmaceutical Research Center, AbClon Inc., #1401, Ace Twin Tower1, 285 Digital-Ro, Guro-Gu, Seoul, Korea.
Lee HJ; Biopharmaceutical Research Center, AbClon Inc., #1401, Ace Twin Tower1, 285 Digital-Ro, Guro-Gu, Seoul, Korea.
Park JH; Biopharmaceutical Research Center, AbClon Inc., #1401, Ace Twin Tower1, 285 Digital-Ro, Guro-Gu, Seoul, Korea.
Cui L; Biopharmaceutical Research Center, AbClon Inc., #1401, Ace Twin Tower1, 285 Digital-Ro, Guro-Gu, Seoul, Korea.
Lee TB; Biopharmaceutical Research Center, AbClon Inc., #1401, Ace Twin Tower1, 285 Digital-Ro, Guro-Gu, Seoul, Korea.
Hwang IS; Biopharmaceutical Research Center, AbClon Inc., #1401, Ace Twin Tower1, 285 Digital-Ro, Guro-Gu, Seoul, Korea.
Lee YH; Biopharmaceutical Research Center, AbClon Inc., #1401, Ace Twin Tower1, 285 Digital-Ro, Guro-Gu, Seoul, Korea.
Lee YJ; Biopharmaceutical Research Center, AbClon Inc., #1401, Ace Twin Tower1, 285 Digital-Ro, Guro-Gu, Seoul, Korea.
Porazzi P; Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, 3400 Civic Center Boulevard, Perelman Center for Advanced Medicine, SPE 8-112, Philadelphia, PA, 19104, USA.; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Liu D; Department of Pathology, Immunology and Laboratory Medicine, Rutgers New Jersey Medical School, Newark, NJ, USA.
Lee Y; Biopharmaceutical Research Center, AbClon Inc., #1401, Ace Twin Tower1, 285 Digital-Ro, Guro-Gu, Seoul, Korea.
Kim JH; Biopharmaceutical Research Center, AbClon Inc., #1401, Ace Twin Tower1, 285 Digital-Ro, Guro-Gu, Seoul, Korea.
Lee JS; Biopharmaceutical Research Center, AbClon Inc., #1401, Ace Twin Tower1, 285 Digital-Ro, Guro-Gu, Seoul, Korea. .
Yoon DH; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-Ro 43-Gil, Songpa-Gu, Seoul, Korea. .
Chung J; Cancer Research Institute, Seoul National University College of Medicine, Suite 510, Samsung Cancer Research Building, 103 Daehak-Ro, Jongno-Gu, Seoul, Korea. .
Ruella M; Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, 3400 Civic Center Boulevard, Perelman Center for Advanced Medicine, SPE 8-112, Philadelphia, PA, 19104, USA. .; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA. .; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. .
Show more
Source:
Molecular cancer [Mol Cancer] 2023 Dec 09; Vol. 22 (1), pp. 200. Date of Electronic Publication: 2023 Dec 09.
Publication Type:
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:
Lymphoma, Non-Hodgkin*/therapy
Lymphoma, Non-Hodgkin*/metabolism
Receptors, Chimeric Antigen*/metabolism
Receptors, Antigen, T-Cell*/antagonists & inhibitors
Humans ; Antibodies ; Antigens, CD19 ; Epitopes/metabolism ; Immunotherapy, Adoptive/adverse effects ; Neoplasm Recurrence, Local/metabolism
Academic Journal
Full Text  Link opens in a new window Full TextDetails
Title:
Renomegaly and acute kidney injury as primary manifestations of non-Hodgkin's lymphoma: a report of three cases.
Authors:
Bai Y; Department of Nephrology, Faculty of Kidney Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Zheng Y; Department of Pathology, Faculty of Kidney Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Zhang Q; Department of Nephrology, Faculty of Kidney Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Jiang Q; Department of Nephrology, Faculty of Kidney Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Diao Z; Department of Nephrology, Faculty of Kidney Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Guo W; Department of Nephrology, Faculty of Kidney Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Liu S; Department of Nephrology, Faculty of Kidney Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, China. .
Liu W; Department of Nephrology, Faculty of Kidney Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, China. .
Show more
Source:
Diagnostic pathology [Diagn Pathol] 2023 Dec 08; Vol. 18 (1), pp. 133. Date of Electronic Publication: 2023 Dec 08.
Publication Type:
Case Reports; Journal Article
MeSH Terms:
Lymphoma, Non-Hodgkin*/complications
Lymphoma, Non-Hodgkin*/diagnosis
Lymphoma, Non-Hodgkin*/pathology
Lymphoma*
Lymphoma, T-Cell*
Leukemia*
Acute Kidney Injury*/etiology
Adult ; Female ; Humans
Academic Journal
Full Text  Link opens in a new window Full TextDetails
Title:
Clinical efficacy and safety of subcutaneous rituximab in non-Hodgkin lymphoma: a systematic literature review and meta-analysis.
Authors:
Si T; Department of Hematology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.
Ma X; Department of Hematology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.
Zhu W; Department of Hematology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.
Zhou Y; Department of Hematology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.
Show more
Source:
Hematology (Amsterdam, Netherlands) [Hematology] 2023 Dec; Vol. 28 (1), pp. 2284047. Date of Electronic Publication: 2023 Nov 27.
Publication Type:
Meta-Analysis; Systematic Review; Journal Article; Review
MeSH Terms:
Lymphoma, Non-Hodgkin*/drug therapy
Lymphoma, Non-Hodgkin*/etiology
Lymphoma, Follicular*/chemically induced
Lymphoma, Follicular*/drug therapy
Lymphoma, Large B-Cell, Diffuse*/drug therapy
Humans ; Rituximab/adverse effects ; Treatment Outcome ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Academic Journal
Full Text  Link opens in a new window Full TextDetails
Title:
Clinical characteristics and prognostic factors for primary pediatric and adolescent Non-Hodgkin Lymphomas of the gastrointestinal tract: a population-based study.
Authors:
Wu P; Department of Pediatric Surgery, Northwest Women's and Children's Hospital, Xi'an, Shaanxi, China.
Zhu D; Department of Pediatric Surgery, The First People's Hospital of Lianyungang, Haizhou District, Lianyungang, People's Republic of China.
Lou Y; Department of Pediatric Surgery, Hangzhou Children's Hospital, Hangzhou, Zhejiang, China.
Wang X; Department of Radiation Oncology, The Third Hospital of Nanchang, Nanchang, 330025, Jiangxi, China. .
Show more
Source:
World journal of surgical oncology [World J Surg Oncol] 2023 Nov 15; Vol. 21 (1), pp. 353. Date of Electronic Publication: 2023 Nov 15.
Publication Type:
Journal Article
MeSH Terms:
Lymphoma, Non-Hodgkin*/epidemiology
Lymphoma, Non-Hodgkin*/therapy
Lymphoma, Large B-Cell, Diffuse*/drug therapy
Gastrointestinal Neoplasms*/therapy
Gastrointestinal Neoplasms*/drug therapy
Humans ; Child ; Adolescent ; Infant ; Child, Preschool ; Young Adult ; Adult ; Prognosis ; Cohort Studies ; Stomach/pathology ; Retrospective Studies
Academic Journal
Full Text  Link opens in a new window Full TextDetails
Title:
Tongue and teeth hyperpigmentation in etoposide, prednisolone, vincristine, and cyclophosphamide regimen in the treatment of cutaneous lymphoma.
Authors:
Morabad SS; Department of Pharmacy Practice, B. V. V. S. Hanagal Shri Kumareshwar College of Pharmacy, Bagalkote, Karnataka, India.
Khan ZU; Department of Pharmacy Practice, B. V. V. S. Hanagal Shri Kumareshwar College of Pharmacy, Bagalkote, Karnataka, India.
Gad R; Department of Pharmacy Practice, B. V. V. S. Hanagal Shri Kumareshwar College of Pharmacy, Bagalkote, Karnataka, India.
Kallur N; Department of Pharmacy Practice, B. V. V. S. Hanagal Shri Kumareshwar College of Pharmacy, Bagalkote, Karnataka, India.
Madhabhavi IV; Department of Medical and Pediatric Oncology and Hematology, Kerudi Cancer Hospital, Bagalkote, Karnataka, India.
Shalavadi MH; Department of Pharmacy Practice, B. V. V. S. Hanagal Shri Kumareshwar College of Pharmacy, Bagalkote, Karnataka, India.
Mangannavar CV; Department of Pharmacy Practice, B. V. V. S. Hanagal Shri Kumareshwar College of Pharmacy, Bagalkote, Karnataka, India.
Show more
Source:
Indian journal of pharmacology [Indian J Pharmacol] 2023 Nov-Dec; Vol. 55 (6), pp. 405-407.
Publication Type:
Case Reports; Journal Article
MeSH Terms:
Lymphoma, Non-Hodgkin*/drug therapy
Lymphoma, Non-Hodgkin*/pathology
Lymphoma*/drug therapy
Skin Neoplasms*
Hyperpigmentation*/chemically induced
Hyperpigmentation*/drug therapy
Humans ; Vincristine/adverse effects ; Etoposide/adverse effects ; Prednisolone/adverse effects ; Prednisone/therapeutic use ; Doxorubicin/adverse effects ; Cyclophosphamide/adverse effects ; Tongue/pathology ; Antineoplastic Combined Chemotherapy Protocols/adverse effects
Academic Journal
Full Text  Link opens in a new window Full TextDetails
Title:
Gemcitabine-based conditioning compared to BEAM/BEAC conditioning prior to autologous stem cell transplantation for non-Hodgkin lymphoma: No difference in outcomes.
Authors:
Liu H; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.; Tianjin Institutes of Health Science, Tianjin, China.
Zou H; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.; Tianjin Institutes of Health Science, Tianjin, China.
Shan D; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.; Tianjin Institutes of Health Science, Tianjin, China.
Liu W; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.; Tianjin Institutes of Health Science, Tianjin, China.
Huang W; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.; Tianjin Institutes of Health Science, Tianjin, China.
Sui W; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.; Tianjin Institutes of Health Science, Tianjin, China.
Deng S; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.; Tianjin Institutes of Health Science, Tianjin, China.
Wang T; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.; Tianjin Institutes of Health Science, Tianjin, China.
Lv R; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.; Tianjin Institutes of Health Science, Tianjin, China.
Fu M; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.; Tianjin Institutes of Health Science, Tianjin, China.
Xu Y; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.; Tianjin Institutes of Health Science, Tianjin, China.
Yi S; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.; Tianjin Institutes of Health Science, Tianjin, China.
An G; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.; Tianjin Institutes of Health Science, Tianjin, China.
Zhao Y; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.; Tianjin Institutes of Health Science, Tianjin, China.
Qiu L; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.; Tianjin Institutes of Health Science, Tianjin, China.
Zou D; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.; Tianjin Institutes of Health Science, Tianjin, China.
Show more
Source:
Cancer medicine [Cancer Med] 2024 Jan; Vol. 13 (2), pp. e6965.
Publication Type:
Journal Article
MeSH Terms:
Hematopoietic Stem Cell Transplantation*/methods
Lymphoma, Non-Hodgkin*/drug therapy
Humans ; Carmustine/adverse effects ; Gemcitabine ; Melphalan/adverse effects ; Retrospective Studies ; Transplantation, Autologous/methods ; Cyclophosphamide/therapeutic use ; Etoposide/adverse effects ; Cytarabine/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Transplantation Conditioning/methods
Academic Journal
Full Text  Link opens in a new window Full TextDetails
Title:
Characteristics and outcomes of children, adolescents and young adults with relapsed/refractory non-hodgkin lymphoma undergoing autologous stem cell transplant.
Authors:
Pasvolsky O; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Bassett RL; Department of Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Ghanem S; Department of Medicine, Alpert Medical School of Brown University, Providence, RI, USA.
Cuglievan B; Department of Pediatrics Patient Care, Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Tewari P; Department of Pediatrics Patient Care, Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Hosing C; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center Unit 0432, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
Srour S; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center Unit 0432, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
Ramdial J; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center Unit 0432, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
Mahadeo KM; Department of Pediatrics Patient Care, Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Khazal S; Department of Pediatrics Patient Care, Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Petropoulos D; Department of Pediatrics Patient Care, Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Popat U; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center Unit 0432, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
Qazilbash M; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center Unit 0432, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
Kebriaei P; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center Unit 0432, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
Champlin R; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center Unit 0432, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
Shpall EJ; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center Unit 0432, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
Nieto Y; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center Unit 0432, 1515 Holcombe Blvd, Houston, TX, 77030, USA. .
Show more
Source:
BMC cancer [BMC Cancer] 2023 Dec 20; Vol. 23 (1), pp. 1258. Date of Electronic Publication: 2023 Dec 20.
Publication Type:
Journal Article
MeSH Terms:
Hematopoietic Stem Cell Transplantation*
Lymphoma, Large B-Cell, Diffuse*/therapy
Lymphoma, Non-Hodgkin*/therapy
Stem Cell Transplantation*/adverse effects
Adolescent ; Adult ; Aged ; Child ; Female ; Humans ; Male ; Young Adult ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Transplantation, Autologous ; Treatment Outcome
Academic Journal
Full Text  Link opens in a new window Full TextDetails
Title:
Autologous Stem Cell Transplant in Hodgkin's and Non-Hodgkin's Lymphoma, Multiple Myeloma, and AL Amyloidosis.
Authors:
Alnasser SM; Department of Pharmacology and Toxicology, Unaizah College of Pharmacy, Qassim University, Buraydah 51452, Saudi Arabia.
Alharbi KS; Department of Pharmacology and Toxicology, Unaizah College of Pharmacy, Qassim University, Buraydah 51452, Saudi Arabia.
Almutairy AF; Department of Pharmacology and Toxicology, Unaizah College of Pharmacy, Qassim University, Buraydah 51452, Saudi Arabia.
Almutairi SM; Unaizah College of Pharmacy, Qassim University, Buraydah 52571, Saudi Arabia.
Alolayan AM; Unaizah College of Pharmacy, Qassim University, Buraydah 52571, Saudi Arabia.
Show more
Source:
Cells [Cells] 2023 Dec 18; Vol. 12 (24). Date of Electronic Publication: 2023 Dec 18.
Publication Type:
Journal Article; Review
MeSH Terms:
Hematopoietic Stem Cell Transplantation*
Multiple Myeloma*/therapy
Immunoglobulin Light-chain Amyloidosis*/therapy
Lymphoma, Non-Hodgkin*/therapy
Humans ; Transplantation, Autologous ; Stem Cell Transplantation
Academic Journal
Full Text  Link opens in a new window Full TextDetails
Title:
Effect and Safety of Orelabrutinib and Lenalidomide Plus R-mini CDOP in Relapsed/Refractory Aggressive B-cell Non-Hodgkin Lymphoma
Authors:
Shang Y; Shandong First Medical University & Shandong Academy of Medical Sciences, Shandong, China
Zhao H; Central Hospital Affiliated to Shandong First Medical University, Shandong, China
Li D; Central Hospital Affiliated to Shandong First Medical University, Shandong, China
Show more
Source:
Turkish journal of haematology : official journal of Turkish Society of Haematology [Turk J Haematol] 2023 Dec 05; Vol. 40 (4), pp. 284-285. Date of Electronic Publication: 2023 Sep 01.
Publication Type:
Journal Article
MeSH Terms:
Lymphoma, Non-Hodgkin*/drug therapy
Lymphoma, Large B-Cell, Diffuse*/drug therapy
Humans ; Lenalidomide/adverse effects ; Rituximab/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Treatment Outcome
Academic Journal
Full Text  Link opens in a new windowDetails
Title:
Specific KIR-HLA genotypes predict outcomes in refractory or relapsed primary central nervous system lymphoma.
Authors:
Lin Z; Department of Hematology, Huashan Hospital, Fudan University, Shanghai, People's Republic of China.
Xu H; Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.
Ma J; Department of Hematology, Huashan Hospital, Fudan University, Shanghai, People's Republic of China.
Ma Y; Department of Hematology, Huashan Hospital, Fudan University, Shanghai, People's Republic of China.
Li Q; Department of Hematology, Huashan Hospital, Fudan University, Shanghai, People's Republic of China.
Kang H; Department of Hematology, Huashan Hospital, Fudan University, Shanghai, People's Republic of China.
Zhang M; Department of Hematology, Huashan Hospital, Fudan University, Shanghai, People's Republic of China.
Chen B; Department of Hematology, Huashan Hospital, Fudan University, Shanghai, People's Republic of China.
Show more
Source:
Hematology (Amsterdam, Netherlands) [Hematology] 2023 Dec; Vol. 28 (1), pp. 2243424.
Publication Type:
Journal Article
MeSH Terms:
Lymphoma, Non-Hodgkin*/drug therapy
Central Nervous System Neoplasms*/drug therapy
Central Nervous System Neoplasms*/genetics
Central Nervous System Neoplasms*/pathology
Humans ; Adult ; Middle Aged ; Aged ; Temozolomide/therapeutic use ; Retrospective Studies ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cytarabine ; Genotype ; HLA-B Antigens/therapeutic use ; Central Nervous System/pathology
Academic Journal
Full Text  Link opens in a new window Full TextDetails
Title:
Prediction and prognostic potential of NR3C1 gene expression level in DLBCL patients.
Authors:
Yan C; Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, People's Republic of China.; The Second Affiliated Hospital of Fujian Medical University, Quanzhou, People's Republic of China.
He X; Department of Pathology, Beijing Tiantan Hospital, Capital Medical University, Beijing, People's Republic of China.
Qi R; Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, People's Republic of China.
Cao L; Nanyang Second General Hospital, Nanyang, People's Republic of China.
Zheng S; Gannan Medical University, Ganzhou, People's Republic of China.
Huang C; Gannan Medical University, Ganzhou, People's Republic of China.
Yang P; Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, People's Republic of China.
Wang J; Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, People's Republic of China.
Zhu M; Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, People's Republic of China.
Li S; Department of Pathology, Beijing Tiantan Hospital, Capital Medical University, Beijing, People's Republic of China.
Dong G; Department of Pathology, Beijing Tiantan Hospital, Capital Medical University, Beijing, People's Republic of China.
Jing H; Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, People's Republic of China.
Zhang W; Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, People's Republic of China.
Liu X; Department of Respiratory Medicine, First Affiliated Hospital Gannan Medical University, Ganzhou, People's Republic of China.
Show more
Source:
Hematology (Amsterdam, Netherlands) [Hematology] 2023 Dec; Vol. 28 (1), pp. 2251199.
Publication Type:
Journal Article
MeSH Terms:
Lymphoma, Large B-Cell, Diffuse*/genetics
Lymphoma, Non-Hodgkin*
Humans ; Prognosis ; L-Lactate Dehydrogenase ; Gene Expression ; Receptors, Glucocorticoid
Academic Journal
Full Text  Link opens in a new window Full TextDetails
Title:
A phase II study of lenalidomide and rituximab (R2) combination in patients with high-risk refractory/relapsed diffuse large B-cell lymphoma.
Authors:
Noel R; Department of Hematology, Institut Paoli-Calmettes, Marseille, France.
Zemmour C; Department of Clinical Research and Innovation - Biostatistics & Methodology Unit, Marseille, France.; Aix Marseille Univ, INSERM, IRD, SESSTIM, Marseille, France.
Montes de Oca C; Department of Hematology, Institut Paoli-Calmettes, Marseille, France.
Belmecheri N; Department of Hematology, Institut Paoli-Calmettes, Marseille, France.
Aurran-Schleinitz T; Department of Hematology, Institut Paoli-Calmettes, Marseille, France.
Coso D; Department of Hematology, Institut Paoli-Calmettes, Marseille, France.
Lopez Almeida L; Department of Clinical Research and Innovation - Sponsoring Unit, Institut Paoli-Calmettes, Marseille, France.
Mescam L; Department of Pathology, Institut Paoli-Calmettes, Marseille, France.
Vey N; Department of Hematology, Institut Paoli-Calmettes, Aix Marseille Univ, CNRS, INSERM, CRCM, Marseille, France.
Bladé JS; Department of Oncology and Hematology, Sainte Anne Military Hospital, Toulon, France.
Slama B; Department of Hematology, Centre Hospitalier Raoul Follereau, Avignon, France.
Bouabdallah R; Department of Hematology, Institut Paoli-Calmettes, Marseille, France.
Schiano de Colella JM; Department of Hematology, Institut Paoli-Calmettes, Marseille, France.
Show more
Source:
Hematology (Amsterdam, Netherlands) [Hematology] 2023 Dec; Vol. 28 (1), pp. 2207948.
Publication Type:
Clinical Trial, Phase II; Journal Article
MeSH Terms:
Lymphoma, Non-Hodgkin*/drug therapy
Lymphoma, Large B-Cell, Diffuse*
Humans ; Aged ; Rituximab/adverse effects ; Lenalidomide/adverse effects ; Prospective Studies ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Treatment Outcome
Academic Journal
Full Text  Link opens in a new window Full TextDetails
Title:
Copanlisib population pharmacokinetics from phase I-III studies and exposure-response relationships in combination with rituximab.
Authors:
Morcos PN; Bayer HealthCare Pharmaceuticals, Inc., Whippany, New Jersey, USA.
Moss J; BAST Inc. Limited, Leicester, UK.
Austin R; BAST Inc. Limited, Leicester, UK.
Hiemeyer F; Bayer AG, Berlin, Germany.
Zinzani PL; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli', Bologna, Italy.; Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy.
Beckert V; Bayer AG, Berlin, Germany.
Mongay Soler L; Bayer HealthCare Pharmaceuticals, Inc., Whippany, New Jersey, USA.
Childs BH; Bayer HealthCare Pharmaceuticals, Inc., Whippany, New Jersey, USA.
Garmann D; Bayer AG, Berlin, Germany.
Show more
Source:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2023 Nov; Vol. 12 (11), pp. 1666-1686. Date of Electronic Publication: 2023 Jun 30.
Publication Type:
Journal Article
MeSH Terms:
Lymphoma, Non-Hodgkin*/drug therapy
Humans ; Antineoplastic Combined Chemotherapy Protocols ; Pyrimidines ; Quinazolines ; Rituximab/therapeutic use ; Clinical Trials, Phase I as Topic ; Clinical Trials, Phase II as Topic ; Clinical Trials, Phase III as Topic
Academic Journal
Full Text  Link opens in a new window Full TextDetails
Showing 1-20 from 3124 results

We use cookies to help identify your computer so we can tailor your user experience, track shopping basket contents and remember where you are in the order process.